Table 6.

The primary scientific discoveries of the 25 references with strong citations bursts.

Rank	Strength	Main research content
1	59.76	Identified alterations of the human gastrointestinal microbiome in liver cirrhosis (Shen et al., 2014)
2	53.38	Cirrhosis is accompanied by progressive alterations in the gastrointestinal microbiome, which become more severe during decompensation (Bajaj et al., 2014b)
3	39.74	The gut-liver axis is the pathophysiological premise for gut-centered therapy in liver disease (Albillos et al., 2020)
4	39.56	Patients with cirrhosis have different fecal microbial communities compared to healthy individuals (Chen et al., 2011)
5	39.29	Dysbiosis mediated by inflammasomes controls the progression of NAFLD and adiposity (Henao-Mejia et al., 2012)
6	36.05	The combination of liver injury and intestinal dysbiosis contributes to the development of liver disease (Schnabl and Brenner, 2014)
7	35.38	Nonalcoholic steatohepatitis patients’ gut microbiomes were characterized (Zhu et al., 2013)
8	33.73	Rifaximin substantially decreased the risk of hepatic encephalopathy in cirrhotic patients (Bass et al., 2010)
9	32.77	Gut dysbiosis and a change in the gut microbiota’s metabolic function are associated with the severity of nonalcoholic fatty liver disease (Boursier et al., 2016)
10	29.63	Pathological bacterial translocation in liver cirrhosis (Wiest et al., 2014)
11	29.5	The gut microbiome is dramatically altered in patients with hepatic encephalopathy and is associated with cognition (Bajaj et al., 2012b)
12	28.84	This study investigates the effectiveness of obeticholic acid in treating non-alcoholic steatohepatitis in adult patients (Neuschwander-Tetri et al., 2015)
13	28.4	The disruption of intercellular tight junctions in the intestines may lead to an increase in intestinal permeability, which may have a substantial effect on the development of hepatic fat deposition (Miele et al., 2009)
14	26.62	The gut microbiota’s influence on the fecal bile acid composition in individuals with cirrhosis (Kakiyama et al., 2013)
15	26.43	In cirrhosis and hepatic encephalopathy, the colonic mucosal microbiome is distinct from the stool microbiome and is associated with cognition and inflammation (Bajaj et al., 2012a)
16	26.26	A comprehensive analysis of microbiome characteristics for human NAFLD (Aron-Wisnewsky et al., 2020)
17	25.18	Practice guidelines for hepatic encephalopathy published in 2014 (Vilstrup et al., 2014)
18	24.53	Rifaximin modulates the metabiome in patients with cirrhosis and mild hepatic encephalopathy (Bajaj et al., 2013)
19	24.35	A microbiome panel based on the metagenome can accurately diagnose advanced fibrosis (Loomba et al., 2017)
20	21.28	NAFLD development may be influenced by intestinal microbiota (Mouzaki et al., 2013)
21	20.48	The central role of the microbiome in NAFLD (Leung et al., 2016)
22	20.46	Identified the diagnostic criteria of acute-on-chronic liver failure and described the development of this syndrome in European patients with acute decompensation (Moreau et al., 2013)
23	20.37	Through the senescence secretome, an obesity-induced intestinal microbial metabolite boosts liver cancer (Yoshimoto et al., 2013)
24	19.97	Infections quadruple the mortality rate in cirrhotic patients (Arvaniti et al., 2010)
25	19.76	The impact of Lactobacillus GG on the gut microbiota, metabolome, and endotoxemia in individuals diagnosed with cirrhosis is being investigated (Bajaj et al., 2014a)